The DrugBank accession number for rimegepant is DB15484 [1].
What is Rimegepant Used For?
Rimegepant is a medication used for the acute treatment of migraine with or without aura in adults [1]. It is also used for the preventive treatment of episodic migraine in adults [1].
How Does Rimegepant Work?
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. It works by blocking the activity of CGRP, a molecule that is thought to play a role in migraine [1].
When Did Rimegepant Receive FDA Approval?
Rimegepant was first approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in December 2019 [2]. It received approval for the preventive treatment of episodic migraine in June 2021 [3].
What Are the Potential Side Effects of Rimegepant?
Common side effects of rimegepant include nausea and upper abdominal pain [1]. More serious side effects, though rare, can occur [1].
Who Manufactures Rimegepant?
Rimegepant is manufactured by Biohaven Pharmaceuticals [1].
Are There Any Drug Interactions with Rimegepant?
Rimegepant can interact with certain other medications, and it is important to discuss all current medications with a healthcare provider before starting rimegepant [1].
Where Can I Find More Information on Rimegepant's Patents and Exclusivity?
Information regarding the patent status and exclusivity periods for rimegepant can be found on DrugPatentWatch.com [4].
What Are Other Migraine Treatments?
Other classes of medications used for migraine treatment include triptans, ergots, and other CGRP antagonists [1].
How is Rimegepant Different from Other CGRP Antagonists?
Rimegepant is an oral CGRP receptor antagonist. Other CGRP antagonists may be administered intravenously or subcutaneously [1].
What is the Difference Between Acute and Preventive Migraine Treatment?
Acute treatment is used to stop a migraine headache once it has started, while preventive treatment aims to reduce the frequency and severity of migraine attacks [1]. Rimegepant is approved for both acute and preventive treatment of episodic migraine [1].
Sources:
[1] DrugBank: Rimegepant
[2] FDA approves Nurtec ODT (rimegepant) for the acute treatment of migraine in adults
[3] Biohaven Announces FDA Approval of NURTEC® ODT (rimegepant) for the Preventive Treatment of Episodic Migraine
[4] DrugPatentWatch.com